Subscribe To

Price Alert Latest News Economic Calendar News

STVN / Stevanato Group S.p.A. (STVN) CEO Franco Moro on Q1 2022 Results - Earnings Call Transcript

Stevanato Group S.p.A. (NYSE:STVN ) Q1 2022 Results Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Miles - Head of Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer and Chief Operating Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America John Kreger - William Blair Dave Windley - Jefferies Paul Knight - KeyBanc Tim Daley - Wells Fargo John Sourbeer - UBS Drew Ranieri - Morgan Stanley Lisa Miles Good morning, and thank you for joining us. Read More

Demo Live Account See Partner Details

Content Topics

Stevanato

Group

STVN

Franco

Moro

2022

Results

S p a

stvn

Earnings

Transcript

Stock

Posted: May 14 2022, 12:12

Author Name: Seeking Alpha

STVN News

By Seeking Alpha
October 31, 2023

Stevanato Group S.p.A. (STVN) Q3 2023 Earnings Call Transcript

By Zacks Investment Research
October 27, 2023

TAK vs. STVN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STV

By Zacks Investment Research
October 11, 2023

USNA or STVN: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But w

By Seeking Alpha
September 15, 2023

Stevanato: Secular Tailwinds In Biologics Support Downstream Demand

Stevanato Group is a global provider of drug containment with a CAPEX growth plan to support growth and reach new geographical diversification. Balanc

By Zacks Investment Research
September 11, 2023

All You Need to Know About Stevanato (STVN) Rating Upgrade to Buy

Stevanato (STVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the

By Zacks Investment Research
June 19, 2023

Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?

Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help th

By Seeking Alpha
June 14, 2023

Stevanato Group: Undeniable Quality, But Lacking Upside

Stevenato Group is a Pharmaceutical Manufacturing leader, generating 15% net income margins annually. The company has developed a global customer base

By Business Wire
May 24, 2023

Stevanato Group to Present at Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnost

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.